University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Francis Yao, MD

Francis Yao, MD

Associate Clinical Professor, Department of Medicine (Gastroenterology), UCSF

Research Summary

Dr. Francis Yao is a gastroenterologist who serves as medical director of the UCSF Liver Transplant Program. He also directs the UCSF Liver Transplant Outreach and Community Liaison Program.

In his research, Yao is interested in liver cancer treatment, particularly as related to liver transplants. He has contributed to important publications in this area. His other research interests include hepatitis B infection and outcomes for patients undergoing liver transplantation.

Selected Publications

  1. Mehta N, Yao FY. Reply to HEP-20-0970. Hepatology. 2020 Jun 24.
    View on PubMed
  2. Silverstein J, Roll G, Dodge JL, Grab JD, Yao FY, Mehta N. Donation after Circulatory Death is Associated with Similar Post-Transplant Survival in All but the Highest Risk Hepatocellular Carcinoma Patients. Liver Transpl. 2020 Jun 12.
    View on PubMed
  3. Kronish K, Freise CE, Yao FY. Bacchus Listed for a Liver Transplant: Comment. Anesthesiology. 2020 Jun; 132(6):1593.
    View on PubMed
  4. Mehta N, Bhangui P, Yao FY, Mazzaferro V, Toso C, Akamatsu N, Durand F, Ijzermans J, Polak W, Zheng S, Roberts JP, Sapisochin G, Hibi T, Kwan NM, Ghobrial M, Soin A. Liver Transplantation for Hepatocellular Carcinoma. Working Group Report from the ILTS Transplant Oncology Consensus Conference. Transplantation. 2020 Jun; 104(6):1136-1142.
    View on PubMed
  5. Brondfield MN, Dodge JL, Hirose R, Heimbach J, Yao FY, Mehta N. Unfair Advantages for Hepatocellular Carcinoma Patients Listed for Liver Transplant in Short-Wait Regions Following 2015 Hepatocellular Carcinoma Policy Change. Liver Transpl. 2020 May; 26(5):662-672.
    View on PubMed
  6. Rich NE, John BV, Parikh ND, Rowe I, Mehta N, Khatri G, Thomas SM, Anis M, Mendiratta-Lala M, Hernandez C, Odewole M, Sundaram LT, Konjeti VR, Shetty S, Shah T, Zhu H, Yopp AC, Hoshida Y, Yao FY, Marrero JA, Singal AG. Hepatocellular carcinoma demonstrates heterogeneous growth patterns in a multi-center cohort of patients with cirrhosis. Hepatology. 2020 Feb 04.
    View on PubMed
  7. Lee DD, Sapisochin G, Mehta N, Gorgen A, Musto KR, Hajda H, Yao FY, Hodge DO, Carter RE, Harnois DM. Surveillance for HCC after Liver Transplantation: Increased monitoring may yield aggressive treatment options and improved postrecurrence survival. Transplantation. 2020 Jan 13.
    View on PubMed
  8. Verna EC, Patel YA, Aggarwal A, Desai AP, Frenette C, Pillai AA, Salgia R, Seetharam A, Sharma P, Sherman C, Tsoulfas G, Yao FY. Liver transplantation for hepatocellular carcinoma: Management after the transplant. Am J Transplant. 2020 02; 20(2):333-347.
    View on PubMed
  9. Mehta N, Dodge JL, Grab JD, Yao FY. National Experience on Down-Staging of Hepatocellular Carcinoma Before Liver Transplant: Influence of Tumor Burden, Alpha-Fetoprotein, and Wait Time. Hepatology. 2020 Mar; 71(3):943-954.
    View on PubMed
  10. Mehta N, Dodge JL, Yao FY. REPLY. Hepatology. 2019 10; 70(4):1491-1492.
    View on PubMed
  11. Gutin L, Yao F, Dodge JL, Grab J, Mehta N. Comparison of Liver Transplant Wait-List Outcomes Among Patients With Hepatocellular Carcinoma With Public vs Private Medical Insurance. JAMA Netw Open. 2019 Aug 02; 2(8):e1910326.
    View on PubMed
  12. Fidelman N, Johanson C, Kohi MP, Kolli KP, Kohlbrenner RM, Lehrman ED, Taylor AG, Kelley RK, Yao FY, Roberts JP, Kerlan RK. Prospective Phase II trial of drug-eluting bead chemoembolization for liver transplant candidates with hepatocellular carcinoma and marginal hepatic reserve. J Hepatocell Carcinoma. 2019; 6:93-103.
    View on PubMed
  13. DesJardin JT, Manicardi M, Svetlichnaya Y, Kolaitis NA, Papolos AI, Selby VN, Zier LS, Klein L, Aras MA, Yao FY, Roberts JP, De Marco T. Noninvasive estimation of pulmonary vascular resistance improves portopulmonary hypertension screening in liver transplant candidates. Clin Transplant. 2019 07; 33(7):e13585.
    View on PubMed
  14. Sinha J, Mehta N, Dodge JL, Poltavskiy E, Roberts J, Yao F. Are There Upper Limits in Tumor Burden for Down-Staging of Hepatocellular Carcinoma to Liver Transplant? Analysis of the All-Comers Protocol. Hepatology. 2019 10; 70(4):1185-1196.
    View on PubMed
  15. Mehta N, Dodge JL, Hirose R, Roberts JP, Yao FY. Predictors of low risk for dropout from the liver transplant waiting list for hepatocellular carcinoma in long wait time regions: Implications for organ allocation. Am J Transplant. 2019 08; 19(8):2210-2218.
    View on PubMed
  16. Mehta N, Yao FY. What Are the Optimal Liver Transplantation Criteria for Hepatocellular Carcinoma? Clin Liver Dis (Hoboken). 2019 Jan; 13(1):20-25.
    View on PubMed
  17. Mehta N, Dodge JL, Roberts JP, Hirose R, Yao FY. Alpha-Fetoprotein Decrease from > 1,000 to < 500 ng/mL in Patients with Hepatocellular Carcinoma Leads to Improved Posttransplant Outcomes. Hepatology. 2019 03; 69(3):1193-1205.
    View on PubMed
  18. Sherman CB, Behr S, Dodge JL, Roberts JP, Yao FY, Mehta N. Distinguishing Tumor From Bland Portal Vein Thrombus in Liver Transplant Candidates With Hepatocellular Carcinoma: the A-VENA Criteria. Liver Transpl. 2019 02; 25(2):207-216.
    View on PubMed
  19. Lee DD, Samoylova M, Mehta N, Musto KR, Roberts JP, Yao FY, Harnois DM. The mRECIST Classification Provides Insight into Tumor Biology for Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation. Liver Transpl. 2019 02; 25(2):228-241.
    View on PubMed
  20. Mehta N, Monto A, Yao FY. Screening for Hepatocellular Carcinoma to Improve Cancer-Related Mortality: Looking Behind When We Should Be Looking Ahead. Gastroenterology. 2019 03; 156(4):1215-1217.
    View on PubMed

Go to UCSF Profiles, powered by CTSI